U.S. health care conglomerate Johnson & Johnson said on Tuesday it will buy all outstanding shares of Japanese skin care firm Ci:z Holdings Co. that it does not already own for ¥230 billion ($2.05 billion) in cash.
J&J is betting the deal — which will give it ownership of popular brands such as Dr.Ci:Labo, Labo Labo and Genomer — will help it strengthen its international innovation pipeline.
The purchase adds to a flurry of cosmetics deals in Asia in recent years, as global brands seek to expand in a booming region that includes the $53.5 billion Chinese market by leveraging Asian brands' smart online marketing and fast turnaround times for new products.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.